Oncology Institute (TOI) EBIT (2020 - 2026)

Oncology Institute (TOI) has reported EBIT for 7 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.

• EBIT for Q1 2026 came in at -$6.5 million, up 34.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.7 million (up 37.21% YoY), and the FY2025 annual result was -$36.1 million, up 39.98% from the prior year.
• EBIT was -$6.5 million for Q1 2026 at Oncology Institute, up from -$6.9 million in the prior quarter.
• Over five years, EBIT peaked at -$6.5 million in Q1 2026 and troughed at -$32.9 million in Q1 2023.
• Average EBIT over 5 years is -$15.4 million, with a median of -$14.9 million recorded in 2023.
• Year-over-year, EBIT sank 1540.14% in 2022 and jumped 45.32% in 2024.
• Over 5 years, EBIT stood at -$25.1 million in 2022, then soared by 39.04% to -$15.3 million in 2023, then grew by 21.97% to -$11.9 million in 2024, then jumped by 42.1% to -$6.9 million in 2025, then climbed by 5.7% to -$6.5 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$6.5 million in Q1 2026, -$6.9 million in Q4 2025, and -$8.1 million in Q3 2025.